CCCrisanta Cruz-Espindola

Crisanta Cruz-Espindola

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Crisanta Cruz-Espindola has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of the In Vitro Dissolution Profiles for Cyclosporine Formulations

    by Nicole E. Alleva, Hsuan‐Ping Hong, Joan R. Coates, Nai‐Wei Chen, Crisanta Cruz‐Espindola, Dawn M. Boothe

    Atopica (formerly Novartis, now Elanco Animal Health) is the pioneer veterinary‐approved modified cyclosporine authorized by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Despite the availability of several veterinary‐specific generics, human generics are frequently substituted extra‐label in clinical practice. However, therapeutic equivalence in humans does not guarantee equal bioavailability in dogs, whether comparing these products to one another or to Atopica. As a Biopharmaceutics Classification System Class II compound, cyclosporine's oral absorption is primarily determined by its dissolution rate. This study compared the in vivo dissolution profiles of three human cyclosporine products including Neoral (Novartis), TEVA (TEVA Pharmaceuticals), and Apotex (Apotex Inc) with Atopica using a Distek 2100 A system (USP Apparatus 2, 50 rpm, 500 mL deionized water, 37°C). Primary outcomes included visual capsule rupture time and cyclosporine concentration at 7.5, 15, and 30 min, quantified by high‐performance liquid chromatography. Neoral exhibited a shorter mean capsule rupture time compared to Atopica, while TEVA and Apotex showed no difference. At the 30‐min mark, no significant differences in concentrations were observed among the products. While these in vitro results suggest comparable dissolution at a critical absorption 30‐min time point, the shorter capsule rupture time of Neoral highlights formulation‐specific differences. Comprehensive in vivo pharmacokinetic studies are warranted to determine if these human generics are truly interchangeable with Atopica or one another in dogs.

  • Assessment of lipemia interference on phenobarbital quantification using particle-enhanced turbidimetric inhibition immunoassay with Dimension clinical chemistry system and comparison to high-performance liquid chromatography

    by Kamoltip Thungrat, Phabpim Thumarat, Alex L. Jenkins, Crisanta Cruz-Espindola

    Phenobarbital, an anti-seizure medication with a narrow therapeutic window, requires therapeutic drug monitoring (TDM) for safe and effective use. Lipemia is a well-known interferent in turbidimetric immunoassays, yet its impact on phenobarbital quantification compared with high-performance liquid chromatography (HPLC) has not been fully characterized. We evaluated the effect of lipemia on phenobarbital measurement using a particle-enhanced turbidimetric inhibition immunoassay (PETINIA; Dimension Xpand Plus clinical chemistry system, Siemens) versus HPLC. Simulated lipemic plasma was prepared by spiking normal canine plasma with lipid emulsion to achieve predefined lipemia indices. Naturally lipemic TDM samples (index ≥ 4; n = 40) and non-lipemic controls (index ≤ 3, n = 40) were also analyzed. Phenobarbital concentrations were compared before and after lipid reduction by double microcentrifugation using both methods. HPLC performance was stable across all lipemia indices, with consistent retention times (5.0 min), accuracy and precision within acceptance limits, and high linearity ( R ² > 0.999). In contrast, PETINIA had a significant positive bias in lipemic samples, with median bias increasing from 9.1% at index 1 to 100% at index 6. Bias was significantly higher in naturally lipemic samples (median: 74.5%) compared with non‑lipemic controls (1.2%; p < 0.001). PETINIA and HPLC had strong agreement in non-lipemic samples (Passing–Bablok regression, r = 0.99), but poor agreement and proportional positive bias in lipemic samples ( r = 0.16; slope CI [1.01, 1.89]). PETINIA overestimated phenobarbital concentrations in lipemic plasma. Microcentrifugation effectively mitigated lipemic interference and improved agreement with HPLC, supporting the use of microcentrifugation in clinical TDM workflows.